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Abstract
Background
mTOR-Is positively influence the occurrence and course of certain tumors after solid organ
transplantation. The effect of mTOR-Is on the overall incidence of tumors irrespective of
their origin is not entirely clear. Furthermore, conflicting data have been shown on mortality
under mTOR-Is.
Methods
The current literature was searched for prospective randomized controlled renal transplan-
tation trials. There were 1415 trials screened of which 13 could be included (pts. = 5924). A
minimum follow-up of 24 months was mandatory for inclusion. Incidence of malignancies
and patient survival was assessed in meta-analyses.
Results
The average follow-up of all trials was 40.6 months. Malignancy was significantly reduced
under mTOR-Is compared to CNIs (RR 0.70, CI 0.49–0.99, p = 0.046). This effect remained
stable when combined with CNIs (RR 0.58, CI 0.34–1.00, p = 0.05). When NMSCs were
excluded the risk for malignancy remained significantly reduced under mTOR-I therapy
(mono and combi) (RR 0.43, CI 0.24–0.77, p = 0.0046). Graft survival was minimally
decreased under mTOR-Is (RR 0.99, CI 0.98–1.00, p = 0.054). This effect was abrogated
when mTOR-Is were combined with CNIs (RR 0.99, CI 0.97–1.02, p = 0.50). Patient survival
was not different (RR 1.00, CI 0.99–1.01, p = 0.54).
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Conclusions
Posttransplant patients have a lower incidence of malignancy when treated with an mTOR-I
no matter if it is used in combination with CNIs or not. This beneficial effect remains signifi-
cant even when NMSCs are excluded. With currently used mTOR-I-based regimen patient
and graft survival is not different compared to CNI therapies.
Introduction
The number of transplants and the alive transplant population is growing. In the US, an
increase of 9.2% was encountered for annually performed transplants from 2010 to 2015
(OPTN data). This has implications for the medical system. According to an USRDS based
analysis around 15.6% of renal transplant recipients are expected to die within the first three
years after renal transplantation, of these 76.3% with a functioning graft representing 46.8% of
all graft losses [1]. Most of these patients die of cardiovascular problems, followed by infections
and malignancy. The significance of malignancy increases over time. Responsible for only
3.6% of the deaths with functioning graft after the first year post transplantation it increases to
16% within years 2–5 post transplantation approaching the level of infections [2].
Altogether, the incidence of post-transplant malignancies is increased 2- to 4-fold com-
pared to the general population and tumors often show a more aggressive phenotype under
immunosuppression [3–5]. It is a complex field with important different aspects: 1. Depen-
dence on the tumor entities: Certain skin tumors are amongst those with the steepest increase
under immunosuppression. Also, tumor incidence seems particularly high for infection-
related tumors, i.e. lymphomas, cancers of anus, vulva, Kaposi etc. The vast majority of infec-
tion-unrelated tumors is also increased but to a lesser extent while some other tumors, i.e.
breast, prostate etc. do not show an increased incidence [6–8]. 2. Correlation of the tumors
with the transplanted organs: some tumors occur more often with certain organ transplants
(liver cancer with liver transplantation) [9]. 3. Influence of the immunosuppressive drugs: it
has been known for a long time that immunosuppressive therapy itself poses a risk for the
development of certain tumors [10, 11]. Ensuing experimental work could confirm this finding
especially for Azathioprine and CNIs [12, 13]. CsA is classified as carcinogenic by the Interna-
tional Agency for Research on Cancer [14].
Hence, big hopes were raised when anti-tumor activity could be attributed to mTOR-Inhi-
bitors [15]. Since then many reports have appeared comparing Calcineurin- and mTOR-Inhi-
bitors in every possible combination assessing not only the immunological potency but also
looking closely at the tumor incidence.
Mirroring the complexity of this field the findings with respect to tumor incidence or recur-
rence have been inconsistent. Treatment of some tumor entities with mTOR-Is, i.e. Kaposi sar-
coma, has been shown highly efficacious [16]. In patients with hepatocellular carcinoma the
effect was much less convincing and especially in advanced stages of tumor disease overall
and recurrence free survival remained unaffected by mTOR-Is [17, 18]. Nonetheless, intense
research in the oncological field resulted in the approval of mTOR-Is for a variety of malignan-
cies, i.e. renal cell carcinoma, subependymal giant cell astrocytoma, breast cancer, and progres-
sive neuroendocrine tumors of pancreatic origin [16, 19].
In the meantime worrisome data have been published indicating a negative mTOR-I effect
on patient survival [20–23].
mTOR-I for solid organ transplantation
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Altogether it remains unclear to this date if mTOR-Is should be used to reduce the overall
incidence of cancer after solid organ transplantation.
Materials and methods
Identification of the eligible trials
Full reports of controlled prospective trials were searched via PubMed (http://www.ncbi.nlm.
nih.gov), ScienceDirect (http://www.sciencedirect.com) and the Cochrane Central Register of
Controlled Trials (http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_
articles_fs.html) up to April 2017 using the following terms: mTOR-inhibitor OR sirolimus
OR everolimus AND transplant AND malignancy or cancer. The search was performed by
two reviewers (S. W., J. A.).
Inclusion criteria
Only prospective randomized multicenter and two single center renal transplantation trials
were included starting 2002. The quality of the trials was assessed using the Jadad-score (mini-
mum score of 2) and ITT-analysis. These trials were required to have had at least two treat-
ment arms, one with an mTOR-I based immunosuppression either with or without a CNI and
one arm containing an mTOR-I free CNI-based immunosuppression. The mTOR-I had to be
introduced within 3 months after the transplantation as this approach is commonly used in
randomized trials. This selection criterion ensured a long follow-up under mTOR-Is with only
minimal CNI exposure. The retrieved trials were screened for information on posttransplant
malignancies, graft and patient survival. When several publications showed the same cohort of
patients, the information was summarized. Trials were only included when a minimum fol-
low-up of 24 months existed.
Screening and inclusion of the articles was performed by two reviewers (S. W., J. A.).
Data analysis
To summarize the available evidence, we calculated relative risks (RRs) for the incidence of
posttransplant malignancies, graft and patient survival under CNI- and mTOR-I-based immu-
nosuppression. If no malignancy was observed in a study arm 0.5 cases were added to both
study arms to facilitate the calculation of the RR. If the incidence in both study arms was zero
the incidence was set to 1% to receive a RR of 1. Publication bias was assessed by plotting study
results against precision of the study (funnel plots) and the according regression tests [24].
Between study heterogeneity was examined using Q-test for heterogeneity and the I2 statistic
[25]. Accounting for possible heterogeneity between the studies, we fitted random effects mod-
els to derive pooled estimators of the natural logarithms of the RR using the restricted maxi-
mum-likelihood estimator [26]. Standard errors were estimated using incidences and number
of patients per group. All calculations were performed using the metafor package in the statisti-
cal software package R (version 2.14.2). P values below 0.05 were considered significant and all
confidence limits were on the 95% level.
Data extraction and methodologic quality
The following data were extracted from eligible articles by two reviewers (S.W., J.A.): induc-
tion therapy, number of patients per treatment arm, mTOR-I dose, start of mTOR-I treatment
post transplantation, graft and patient survival, trough levels, follow-up period, description,
type and incidence of events of posttransplant malignancy, and statistical analysis of the post-
transplant malignancy under mTOR-Is, mTOR-Is in combination with CNIs and CNIs.
mTOR-I for solid organ transplantation
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Methodological quality was assessed by three reviewers (S.W., J.A., V.H.) using the Jadad
score and Intention to treat (ITT) analysis [27, 28]. The Jadad score addresses the items ran-
domization, blinding and description of drop outs and withdrawals. The score ranges from 0
to 5. A score of at least 3 is being considered to be consistent with sound methodological qual-
ity. ITT was considered another important aspect for methodological quality assessment [29].
In addition, Cochrane Collaboration’s tool was used to further reduce the risk of bias [30].
Results
Included studies
The literature search produced 1415 studies, of which 13 met the inclusion criteria. Thus, a
total number of n = 5924 patients were included (Fig 1). The average follow-up was 40.62
months. The trials were only on kidney transplantation. Eight trials compared mTOR-I with
CNI treatment (S1 Table) and n = 5 mTOR-I+CNI vs. CNI (S2 Table). Of these thirteen trials,
9 RCTs used Sirolimus (SRL) and 4 Everolimus (EVRL). We only included studies with intro-
duction of the mTOR-I within three months post transplantation. Mostly the mTOR-I was
introduced de novo or very early (within the first month; n = 10). The majority used either
monoclonal or polyclonal antibodies as induction therapy (n = 11).
Only longterm analyses on tumor incidence with and without NMSCs were performed.
Furthermore, patient survival and graft survival censored for death were analyzed. The shortest
follow-up duration was 24 months.
Methodological quality
Eleven of the 13 RCTs were considered to be of good methodological quality according to the
Cochrane Collaboration’s tool (S1 and S2 Figs) and the Jadad score (3) (S1 and S2 Tables).
The remaining 2 had a Jadad-score of 2 due to unclear drop out reporting.
Tumor incidence post transplantation—mTOR-I vs. CNI
Treatment with an mTOR-I (n = 8, SIR = 7, ERL = 1) showed a significantly reduced risk for
posttransplant malignancies compared to CNI treatment (RR 0.70, CI 0.49–0.99, p = 0.046)
(Fig 2A). The regression test for funnel plot asymmetry was significant (p = 0.014) and the fun-
nel plot itself reveals some asymmetry in favor of mTOR-I treatment upon visual inspection
(S3 Fig). No heterogeneity between the studies was observed (I2 = 0.0%, Q-Test for heteroge-
neity: p = 0.69).
The analysis excluding NMSCs (n = 6) also revealed a reduced relative risk for the tumor
incidence under mTOR-I treatment (RR 0.55, CI 0.29–1.04, p = 0.066) (Fig 2B). There was no
heterogeneity observed between the studies (I2 = 0.0%, Q-Test for heterogeneity: p = 0.62).
Tumor incidence post transplantation—mTOR-I + CNI vs. CNI
RCTs with a combination therapy (mTOR-I+CNI, n = 5, SIR = 2, ERL = 3) showed a signifi-
cantly reduced risk for the tumor incidence in comparison to CNI therapy (RR 0.58, CNI
0.34–1.00, p = 0.05) (Fig 3A). There was also no funnel plot asymmetry (p = 0.48) (S3 Fig) or
significant heterogeneity observed between RCTs (I2 = 47.21%, Q-Test for heterogeneity:
p = 0.12).
After exclusion of NMSCs (n = 2) there was also a significant difference (RR 0.24, CI 0.09–
0.63, p = 0.0038) (Fig 3B). There was no indication of publication bias in the funnel plot as
indicated by the regression test (p = 1.0) (S3 Fig). Also heterogeneity between the studies was
not significant (I2 = 0.00%, Q-Test for heterogeneity: p = 0.53).
mTOR-I for solid organ transplantation
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Fig 1. Flowchart of the selection of articles. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting Itemsfor Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.
pmed1000097 For more information, visit www.prisma-statement.org.
https://doi.org/10.1371/journal.pone.0194975.g001
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Tumor incidence post transplantation—mTOR-I vs. CNI (monotherapy or
combined with CNI)
Taken together all studies on longterm tumor incidence (n = 13, SIR = 9, ERL = 4), the risk
of posttransplant malignancy was significantly reduced under mTOR-I treatment (RR 0.67,
Fig 2. Malignancies on mTOR-I vs. CNI treatment post transplantation. (A) Forest plot indicating the relative risk of the occurence of malignancies.
1 Latest update by Gatault et al. in 2016. 2 Latest update by Ekberg et al. in 2009. 3 Latest update by Flechner et al. in 2007. 4 Latest update by Guba et al.
in 2012. 5 Latest update by Lebranchu et al. in 2011. (B) Forest plot indicating the relative risk of the occurence of malignancies excluding NMSC’s. 1
Last update by Gatault et al. in 2016. 2 Last update by Felchner et al. in 2007. 3 Last update by Guba et al. in 2012. 4 Last update by Lebranchu et al. in
2011.
https://doi.org/10.1371/journal.pone.0194975.g002
Fig 3. Malignancies on mTOR-I+CNI vs. CNI treatment post transplantation. (A) Forest plot indicating the relative risk of the occurence of
malignancies. 1 Last update by Kumar et al. in 2008. 2 Last update by Cibrik et al. 2013. 3 Last update by Vitko in 2005. (B) Forest plot indicating the
relative risk of the occurence of malignancies excluding NMSC’s. 1 Latest update by Kumar et al. in 2008.
https://doi.org/10.1371/journal.pone.0194975.g003
mTOR-I for solid organ transplantation
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CNI 0.51–0.86, p = 0.002) (Fig 4A). Heterogeneity between the studies was not significant
(I2 = 0.0%, Q-Test for heterogeneity: p = 0.42).
When NMSCs were excluded 8 RCTs could still be included in the statistical analysis.
Here, the relative risk was also significantly reduced under mTOR-Is (RR 0.43, CI 0.24–0.77,
p = 0.0046) (Fig 4B). There was no funnel plot asymmetry (p = 0.55) (S3 Fig) or significant het-
erogeneity between RCTs (I2 = 13.44%, Q-Test for heterogeneity: p = 0.54).
Graft survival (censored for death)—mTOR-I vs. CNI
There were 7 RCTs included in this analysis. SIR was the mTOR-I used in 6 RCTs and EVRL
in 1 RCT.
The ensuing analysis implied a minimal negative effect for the mTOR-I therapy even
though a statistical significance was closely missed (RR 0.99, CI 0.98–1.00, p = 0.054; Fig
5A). The regression test for funnel plot asymmetry was not significant (p = 0.56) (S4 Fig).
There was no heterogeneity between the RCTs (I2 = 18.22%, Q-Test for heterogeneity:
p = 0.17).
Graft survival (censored for death)—mTOR-I + CNI vs. CNI
There were four RCTs (SIR = 1, EVRL = 3) which presented longterm graft survival data cen-
sored for patients’ death. The meta-analysis revealed an estimated combined RR of 0.99 (CI
0.97–1.02, p = 0.50; Fig 5B). There was no indication of publication bias in the funnel plot or
the regression test for asymmetry (p = 0.75) (S4 Fig). Also there was no substantial heterogene-
ity between the studies (I2 = 28.30%, Q-Test for heterogeneity: p = 0.28).
Fig 4. Malignancies on mTOR-I (monotherapy or combined with CNIs) versus CNI treatment post transplantation. (A) Forest plot indicating the
relative risk of the occurence of malignancies. 1 Latest update by Fischer et al. in 2015. 2 Latest update by Ekberg et al. in 2009. 3 Latest update by
Flechner et al. in 2007. 4 Latest update by Guba et al. in 2012. 5 Latest update by Kumar et al. in 2008. 6 Latest update by Lebranchu et al. in 2011. 7 Last
update by Cibrik et al. 2013. 8 Latest update by Vitko et al. in 2005. (B) Forest plot indicating the relative risk of the occurence of malignancies excluding
NMSC’s. 1 Last update by Gatault et al. in 2016. 2 Last update by Flechner et al. in 2007. 3 Last update by Guba et al. in 2012. 4 Last update by Kumar
et al. in 2008. 5 Last update by Lebranchu et al. in 2011.
https://doi.org/10.1371/journal.pone.0194975.g004
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Graft survival (censored for death)—mTOR-I vs. CNI (monotherapy or
combined with CNI)
Taken together all studies with an mTOR-I-treatment arm (monotherapy or in combination
with a CNI) compared to a CNI-based treatment (n = 11, SIR = 7, ERL = 4), the overall graft
survival was statistically superior under CNIs (RR = 0.99; CI 0.98–1.00, p = 0.034) (Fig 5C).
Similar to the analysis of mTOR-I without CNIs vs. CNIs (Fig 5A) the difference was minute
and thus may not have been clinically relevant. There was no indication of publication bias in
Fig 5. Graft survival censored for death post transplantation. (A) Forest plot indicating the graft survival censored for death on mTOR-I vs. CNI
treatment. 1 Latest update by Gatault et al. in 2016. 2 Latest update by Ekberg et al. in 2009. 3 Latest update by Flechner et al. in 2007. 4 Latest update by
Lebranchu et al. in 2011. (B) Forest plot indicating the graft survival censored for death on mTOR-I+CNI vs. CNI. 1 Last update by Cibrik et al. 2013. 2
Latest update by Vitko et al. in 2005. (C) Forest plot indicating the graft survival censored for death on mTOR-I (all) vs. CNI. 1 Latest update by Gatault
et al. in 2016. 2 Latest update by Ekberg et al. in 2009. 3 Latest update by Flechner et al. in 2007. 4 Latest update by Lebranchu et al. in 2011. 5 Last update
by Cibrik et al. 2013. 6 Latest update by Vitko et al. in 2005.
https://doi.org/10.1371/journal.pone.0194975.g005
mTOR-I for solid organ transplantation
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the funnel plot as indicated by the regression test (p = 0.28) (S4 Fig) and no heterogeneity
between studies (I2 = 12.84%, Q-Test for heterogeneity: p = 0.22).
Patient survival post transplantation—mTOR-I vs. CNI
There were 8 RCTs included in this analysis, which compared an mTOR-I- with a CNI-based
treatment. Here, the mTOR-I was given without a CNI. SIR was the mTOR-I used in 7 and
EVRL in 1 RCTs.
The mTOR-I showed a combined estimated RR of 1.00 (CI 0.98–1.01, p = 0.71) compared
with the CNI treatment (Fig 6A). The regression test for funnel plot asymmetry was not signif-
icant (p = 0.40) (S4 Fig). There was no indication of a significant heterogeneity between the
studies (I2 = 0.00%, Q-Test for heterogeneity: p = 0.83).
Patient survival post transplantation—mTOR-I + CNI vs. CNI
Five RCTs (SIR = 2, EVRL = 3) presented longterm patient survival data in this setting. The
meta-analysis revealed an estimated combined RR of 1.00 (CI 0.98–1.01, p = 0.60; Fig 6B).
There was no indication of publication bias in the funnel plot or the regression test for asym-
metry (p = 0.82) (S4 Fig). Also there was no substantial heterogeneity between the studies
(I2 = 0.00%, Q-Test for heterogeneity: p = 0.98).
Patient survival post transplantation—mTOR-I vs. CNI (monotherapy or
combined with CNI)
When all studies with an mTOR-I-treatment arm either in monotherapy or in combination
with a CNI were taken together and compared to a CNI-based treatment (n = 13, SIR = 9,
ERL = 4), the overall patient survival showed a RR of 1.00 (CI 0.99–1.01, p = 0.54; Fig 6C).
There was no indication of publication bias in the funnel plot as indicated by the regression
test (p = 0.25) (S4 Fig). There was also no heterogeneity (I2 = 0.00%, Q-Test for heterogeneity:
p = 0.98).
Discussion
In this analysis the clinical evidence for a reduced incidence of malignancies under mTOR-Is
compared to CNIs was summarized performing a systematic review and meta-analyses on the
most recent and relevant high-quality randomized controlled trials in renal transplantation.
As additional determinants graft and patient survival were analyzed. The results for the patient
survival were of particular interest because a few papers had indicated a poorer survival under
mTOR-I therapy in the recent years [20–23].
Importantly, only data from trials with a minimum follow-up of 24 months, averaging 41
months were included trying to elaborate the effect on malignancy and survival. Thus
n = 5924 randomized pts. could be included making this analysis the largest of its kind with
the longest follow-up to this topic.
Malignancy
The overall tumor incidence in the immunosuppressed transplant patients is 2–4 times higher
compared to the healthy general population [9, 10, 31–33].
We found a significantly reduced incidence of malignancy for an mTOR-I-based immuno-
suppression. This effect remained stable even in combination with CNIs and when all trials
with an mTOR-I-based treatment (with or without CNI) were analyzed together.
mTOR-I for solid organ transplantation
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This was expected and in part shown by others before [23, 34] since mTOR-Is have a partic-
ularly strong and well established effect against NMSCs [35, 36]. Squamous cell and basal cell
carcinoma are the most frequent NMSCs (>90% of all skin cancers under immunosuppres-
sion). These tumors affect ultimately 50% or more of the white transplant recipients and are
thus among the most common tumors under immunosuppression [37]. CsA has been associ-
ated with an increased NMSC incidence [38, 39].
Thus the more intriguing part was the next set of analyses for which NMSCs were excluded.
For this, six studies could be included comparing mTOR-I without CNI vs. CNI. Another two
trials with a comparison mTOR-I + CNI vs. CNI could be added.
Fig 6. Overall patient survival post transplantation. (A) Forest plot indicating the overall patient survival on mTOR-I vs. CNI treatment. 1 Latest
update by Gatault et al. in 2016. 2 Latest update by Ekberg et al. in 2009. 3 Latest update by Flechner et al. in 2007. 4 Latest update by Guba et al. in 2012.
5 Latest update by Lebranchu et al. in 2011. (B) Forest plot indicating the overall patient survival on mTOR-I+CNI vs. CNI treatment. 1 Latest update by
Kumar et al. in 2008. 2 Last update by Cibrik et al. 2013. 3 Latest update by Vitko et al. in 2005. (C) Forest plot indicating the overall patient survival on
mTOR-I (all) vs. CNI treatment. 1 Latest update by Gatault et al. in 2016. 2 Latest update by Ekberg et al. in 2009. 3 Latest update by Flechner et al. in
2007. 4 Latest update by Guba et al. in 2012. 5 Latest update by Kumar et al. in 2008. 6 Latest update by Lebranchu et al. in 2011. 7 Last update by Cibrik
et al. 2013. 8 Latest update by Vitko et al. in 2005.
https://doi.org/10.1371/journal.pone.0194975.g006
mTOR-I for solid organ transplantation
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Taken all these analyses together the RR for malignancy w/o NSMCs was substantially and
significantly reduced (8 trials; RR 0.43, CI 0.24–0.77, p = 0.0046).
Over the past decade a series of meta-analyses and large population-based trials tried to elu-
cidate the mTOR-I anti-tumor effect and outline a certain pattern for cancer incidences after
solid organ transplantation [7–9, 40].
One of the first, Kauffman et al. published registry data from the OPTN/UNOS on
this topic in 2005 [36]. At that time n = 2825 pts. treated with mTOR-Is either with or with-
out CNIs had been reported to the registry. Their conclusion was a significant reduction
of NMSCs and non-skin tumors. One problem here was that SRL users were defined
only by the immunosuppressive regimen at discharge from the hospital and a tumor inci-
dence of 0% in > 500 pts. under mTOR-Is over a follow up of close to 3 years may indicate
underreporting.
In the first meta-analysis on mTOR-I vs. CNIs, no significant difference with respect to
tumor incidence could be reported [41]. Limiting factor here was that only four RCTs with
n = 447 could be included.
More recently, a meta-analysis combined with registry-data showed a 51% reduction
of NMSCs under a SRL-based compared to a CNI-based immunosuppression for renal
transplant recipients while failing to show a benefit with respect to other tumors [42].
Here, included RCTs reached back as far as 1999 including mTOR-I regimen no longer
used nowadays. Follow-up of the included trials ranged from 6 months to 5 years averaging
only 2 years. This may have been simply too short to detect significant effects on tumor
incidence.
Similar data were reported by another meta-analysis on patients after renal transplantation
receiving SRL [23]. Here, NMSCs were significantly reduced by 56% under SRL. The effect
against “tumors other than NMSCs” was ambiguous: when all trials were analyzed together no
effect was seen. Only in subgroup analyses, i.e. on “conversion trials” was a significantly
reduced tumor incidence detectable. These divergent data indicate that certain mTOR-I regi-
men may be more beneficial against tumors than others. Inclusion of “early” trials dating back
to 1999, when higher mTOR-I concentrations and loading doses were common, may have
been responsible for the differences to our analysis.
Contrary to the above mentioned papers we tried to be more stringent about the study
compilation including only trials with currently used mTOR-I regimen and comparable
concentrations.
A Collaborative Transplant Study (CTS)- analysis on n = 78146 first deceased-donor kidney
transplant recipients with a mean follow-up of 4.2 yrs provided more detailed information on
NMSCs [34]. Similar to the other registry analyses the overall incidence of NMSCs but not
“other” tumors was significantly reduced. For this trial, only de novo mTOR-I use was
included and no difference was made between the patients receiving a CNI-free mTOR-I
based regimen or the combination of the two.
The problems inherent to registry data are well known. And they may even be aggravated
for informations which are not the primary focus of the registry. This was recently confirmed
by a comparison of the SRTR with 15 linked cancer registries. Even though US transplant cen-
ters are required to report cancers in transplant recipients to the transplant network, this anal-
ysis revealed an extraordinary lack of accuracy and completeness for the SRTR [43]. The
authors reported an estimated sensitivity for identifying cancer of only 52.5%.
For which tumor entities, other than NMSCs mTOR-Is have a beneficial effect we cannot
tell by this analysis. Furthermore, we cannot exclude the possibility that mTOR-Is are permis-
sive for some tumor entities while inhibiting others as has been postulated for prostate and
renal cancers [42].
mTOR-I for solid organ transplantation
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Graft survival
Our analyses found a statistically significant benefit for CNIs vs. mTOR-Is w/o CNIs. The RR
was 0.99 and thus a clinical relevance questionable. For the combination of mTOR-Is and
CNIs no such effect was seen. It has been repetitively shown that a de novo or an early “mono-
therapy” with an mTOR-I results in a higher percentage of BPARs and a high number of ther-
apy dropouts [44–47]. These problems may be avoided by using the combination of two [48–
50] as is confirmed by our analyses.
Patient survival
Another important aspect of our analysis is that there is no difference in patient survival
(mTOR-I vs. CNI therapy). This is contrary to some reports of the recent years which indicated a
potential threat for patients under mTOR-Is [20–23, 51]. The two most recent reports contained
registry data from ANZDATA [20] and SRTR [51] including patients reaching as far back as
1996 and 2000 respectively. Despite the large number of patients and sophisticated statistical cal-
culation models which can compensate for certain shortcomings, registry data may just not be
appropriate to correctly analyze the survival in this context. Many patients are put on mTOR-Is
for a history of or current malignancy and transplant dysfunction due to CAN—both situations
for which an earlier death would be expected. Furthermore, many patients had been included in
earlier years when higher doses of mTOR-Is were standard. Without doubt “longterm” data
from randomized controlled trials are the most accurate to receive a correct answer on the ques-
tion of survival. The only trial to date that used randomized controlled data and showed a worse
survival under mTOR-Is was the meta-analysis by Knoll et al. [23]. Here, a 43% increased risk of
death under SRL for renal transplant patients was reported. Trial composition may have been at
least in part responsible for these data. Most of the included trials used SRL de novo (76%) and
often with extraordinary high loading and maintenance doses. Importantly, mortality under
“low dose” SRL, as is preferably used nowadays in transplantation was not increased.
Limitations
First, we did not have patient level information from the included RCTs. Second, malignancy
and survival were the primary endpoint in some but not all of the RCTs. However, survival as
the most important outcome variable has certainly been documented accurately. This most
likely holds true also for malignancy events. Post-transplant malignancy and the as of yet
unclear significance of an mTOR-I therapy is a highly relevant aspect. Third, the trials
included patients with varying risk of malignancy: some excluded those with any cancer, while
others excluded only those with a history of non-skin cancer.
Conclusions
Early initiation or conversion to mTORI-I within 3 months of kidney transplantation may
reduce the future risk of cancer, when compared with patients remaining on CNI-based regi-
mens. The primary effect is against NMSCs but there also exists a significant effect against
other tumors. The predominant part of the anti-tumor effect remains present even when
administered in combination with a CNI. There is no increased mortality nor graft loss under
currently used mTOR-I based regimen.
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